Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- BI, Eli Lilly Plan to Submit SGLT-2 Inhibitor Empagliflozin for Approval in Japan, US, and Europe in 2013
January 10, 2013
- Novartis Launches Respiratory Infection Treatment Tobi
January 10, 2013
- Chugai Licenses Novel Anticancer Agent FF284 to Debiopharm of Switzerland
January 10, 2013
- Pharmaceutical Firms’ Leaders Hopeful of New Products and Determined to Build Stronger Business Foundations
January 9, 2013
- AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
- Sanofi Transfers Marketing Rights from Genzyme for Fludara
January 9, 2013
- Ajinomoto Pharmaceuticals Launches Atelec in Vietnam
January 9, 2013
- Novartis Pharma and Eisai Terminate Copromotion Agreement for COPD Therapies
January 9, 2013
- Bayer Yakuhin Files Eylea for Macular Edema Associated with CRVO
January 9, 2013
- Japan Should Invest More in Whole Genome Sequencing and Interpretation of Cancer-related Genomic Abnormalities: Dr Nakagawa of RIKEN
January 9, 2013
- BONAC Offers Solutions to Overcome Difficulties Faced in Development of Nucleic Acid Medicines: Managing Director Mizutani
January 9, 2013
- Nippon Kayaku Ups FY2012 Outlook for Pharma Biz, Anticancer Generics Brisk
January 8, 2013
- Abbott Japan’s Spin-Off AbbVie G.K. Starts Operations in January with CEO Winer
January 8, 2013
- “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
- Sanofi K.K. Acquires DPP-4, SGLT-2 Inhibitors from Novartis, Chugai Aiming for Growth of Its Own Major Products for Diabetes through Synergism
January 7, 2013
- Lilly and BI in Long-term Collaboration; AZ and BMS Expanding Product Lineup
January 7, 2013
- Kowa Acquires 2 Major Products for “Post-Livalo” Era; How to Avoid Competition between Partners Holds Key in Comarketing
January 7, 2013
- Kyowa Kirin to Enhance Nephrology Lineup with DPP-4 Inhibitor; Companies Aiming to Capture Market through “2-Sword” Strategy
January 7, 2013
- Yoshindo, Ajinomoto Pharmaceuticals to Establish Joint Venture in Infusion and Dialysis Business
December 28, 2012
- Kissei Submits Application for Additional Indications for Combination Therapy of Glufast and DPP-4 Inhibitor or Biguanide
December 28, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…